Cardiology Pharmaceuticals
February 9, 2026
Statin Side Effects Might Not be So Bad February 9, 2026
New research in The Lancet suggests that statin underutilization might stem from unfounded safety fears rather than actual risk, after researchers found that 62 out of 66 the drugs’ package-listed adverse effects lack reliable evidence. In an attempt to clear statins’ name, researchers analyzed data from 19 large RCTs to distinguish real statin-associated risks from […]
Cardiology Business
February 5, 2026
Medtronic Acquires CathWorks, Expands Cath Lab Presence February 5, 2026
Using AI algorithms to diagnose and assess coronary artery disease for intervention is about to become more mainstream after medtech giant, Medtronic, agreed to exercise its acquisition rights on AI FFR specialist, CathWorks, for $585M up-front. Until now CathWorks’ FFRangio has only been available in the U.S., Europe, and Japan through Medtronic’s distribution network, but […]
Cardiology Pharmaceuticals
February 2, 2026
CKM’s True Medication Burden February 2, 2026
As cardiology begins to look at the spectrum of cardiovascular-kidney-metabolic disease, new research in JAMA suggests that CKM treatments might face serious adoption challenges due to the sheer number of Americans who both have the disease and qualify for medications. In a search for just how many eligible patients are out there, researchers examined FDA-approved […]
